Dror Ortho-Design, Inc. Q2 2026 Financial Report: Key Highlights and Investor Insights
Summary and Key Points
- Company: Dror Ortho-Design, Inc.
- Quarter Ended: June 30, 2026
- Filing: Form 10-Q (Quarterly Report)
- Ticker: No trading symbol or exchange currently registered; common stock is not listed.
- Stage: Development stage, no material revenues to date, substantial accumulated deficit.
Financial Highlights
- Assets: \$258,936 as of June 30, 2026 (down from \$365,689 at December 31, 2025).
- Stockholders’ Deficit: Negative equity position of (\$2,873,711) as of June 30, 2026, worsening from (\$3,937,520) at December 31, 2025.
- Accumulated Deficit: \$23,315,352 as of June 30, 2026, up from \$22,051,543 at December 31, 2025.
- Working Capital: Negative working capital of (\$3,751,932) as of June 30, 2026.
- Net Loss: (\$1,263,809) for the six months ended June 30, 2026 (compared to a loss of \$1,335,461 for the six months ended June 30, 2025).
- Net Loss per Share: (\$0.00) for the periods reported, due to the extremely high number of shares outstanding.
- Common Shares Outstanding: 976,997,116 as of July 30, 2026.
- Preferred Stock Outstanding: Series A: 5,847,937 shares.
- Additional Paid-in Capital: \$19,279,548 as of June 30, 2026.
- Convertible Debt: Raised \$575,000 during the six months ended June 30, 2026; \$500,000 in the prior year period.
- Stock Issued for Services: 20,000,000 shares issued in respect of future services, valued at \$200,000 during the period.
Critical Business Risks and Going Concern
- Going Concern Warning: The company has not generated material revenues, suffers recurring operating losses, relies on external financing, and faces substantial doubt about its ability to continue as a going concern.
- Dependence on New Capital: Dror Ortho-Design, Inc. is actively seeking new fundraising opportunities to support its operations, repay liabilities, and pursue research and commercialization. There is no assurance such funds can be obtained.
- No Market Listing: The company’s common stock is not listed on any exchange and has no trading symbol.
- Development Stage Risks: The company currently generates no revenue, is in product development, and faces the risk of failure to obtain regulatory approval or achieve market acceptance.
- Extremely High Share Count: With nearly 1 billion shares outstanding and large amounts of potential dilution from anti-dilutive securities (warrants and options), future equity value per share could be significantly affected.
- Potential for Dilution: Over 1.7 billion shares of potentially dilutive securities (warrants, options, preferred stock) exist, likely to dilute existing shareholders if exercised or converted.
- Stock-based Compensation: The company continues to use stock-based compensation as a significant form of payment, indicating cash constraints.
Segment Information and Operations
- Operating Segment: The company operates a single segment focused on the development of its platform. All research and development activities are based in Israel.
- Regional Events: The company’s R&D activities in Israel have not been materially affected by regional conflicts as of the reporting period, but management continues to monitor the situation.
Additional Details and Potential Price-Sensitive Information
- Material Uncertainties: The company’s survival depends on raising additional capital and successful commercialization of its products, both of which remain uncertain.
- Non-Cash Transactions: The issuance of shares for services and stock-based compensation continues, highlighting cash flow pressures.
- No Subsequent Events: The company disclosed no material subsequent events after June 30, 2026.
- Accounting Policies: The unaudited interim financials are prepared in accordance with U.S. GAAP and should be read in conjunction with annual statements. Significant estimates are used for contingencies, accrued expenses, stock-based compensation, and fair value of liabilities.
Shareholder Considerations
- Share Value Risk: Given the company’s negative equity position, ongoing losses, need for capital, and massive potential dilution, current and prospective shareholders should carefully consider the extreme risks involved.
- No Dividend Policy: There is no expectation of dividends, and any recovery of value depends on future commercialization and capital raising success.
- Regulatory and Market Uncertainty: Future value depends on regulatory approvals and actual market acceptance of the company’s products, which are not assured.
- Not a Shell Company: The company certifies it is not a shell company, but its lack of operations and revenues make it highly speculative.
Conclusion
Dror Ortho-Design, Inc. remains a highly speculative development-stage company with no revenues, a substantial accumulated deficit, negative net equity, and an urgent need for new funding. The company’s survival and future value depend on its ability to raise capital, achieve regulatory approvals, and commercialize its platform. The massive number of outstanding and potentially issuable shares poses a significant risk of dilution, which could severely impact future share value. There are currently no material subsequent events or new developments disclosed post-June 2026.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The company described herein is highly speculative, faces significant going concern risk, and may not be suitable for all investors.
